To hear about similar clinical trials, please enter your email below
Trial Title:
Exosome as the Prognostic and Predictive Biomarker in EBC Patients
NCT ID:
NCT05955521
Condition:
Triple Negative Breast Cancer
HER2-positive Breast Cancer
Conditions: Official terms:
Breast Neoplasms
Triple Negative Breast Neoplasms
Study type:
Interventional
Study phase:
N/A
Overall status:
Active, not recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Screening
Masking:
None (Open Label)
Intervention:
Intervention type:
Procedure
Intervention name:
exosome and ctDNA evaluation
Description:
Serial exosome and ctDNA evaluation during follow up period between neoadjuvant
chemotherapy and surveillance after curative surgery.
Arm group label:
CtDNA/Exosome evaluation
Summary:
This study is the experimental study for serial ctDNA and exosome evaluation in EBC
patients
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Early breast cancer
- Planned neoadjuvant chemotherapy
- Triple negative breast cancer or HER2-positive breast cancer
Exclusion Criteria:
- Stage IV breast cancer
- Hormone receptor positive breast cancer
Gender:
Female
Minimum age:
N/A
Maximum age:
N/A
Healthy volunteers:
Accepts Healthy Volunteers
Locations:
Facility:
Name:
Ji-Yeon Kim
Address:
City:
Seoul
Zip:
06351
Country:
Korea, Republic of
Start date:
May 1, 2021
Completion date:
July 1, 2028
Lead sponsor:
Agency:
Samsung Medical Center
Agency class:
Other
Source:
Samsung Medical Center
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05955521
